Developing first-in-class extracellular vesicle therapeutics targeting the underlying causes of atrial fibrillation.
Ottawa, Ontario
Rhythm Biotherapeutics Inc. (RBI) is a pre-clinical spinout of the University of Ottawa Heart Institute, founded in November 2022 by Darryl Davis, a cardiac electrophysiologist pioneering novel therapies to prevent and cure atrial fibrillation (AF). The company has developed a patent pending exosome therapy that, in animal studies, has proven to effectively prevent postoperative atrial fibrillation (POAF). RBI’s therapy uniquely addresses atrial inflammation and fibrosis, the fundamental physiological mechanism driving POAF. RBI is currently seeking investors who will accelerate achieving its next milestones. The obtainable market in North America and Europe for POAF therapy is over US$2B per year and growing.
On-site · Ottawa
Conduct preclinical studies using rodent models of myocardial infarction and atrial fibrosis, including cardiac testing, tissue collection, and preparation for molecular and histological analysis. Maintain rigorous documentation and data integrity, follow biohazard safety procedures, identify additional tasks independently, and help train new lab personnel.